Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Advanced Gastric Cancer

NCT05914610 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer

Interventions

DRUG: Envolimab
DRUG: Fruquintinib
DRUG: Oxaliplatin
DRUG: Tegafur

Sponsor

Fujian Medical University